ODDI logo


What we do

The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies. This initiative is based on juxtaposing high quality drug discovery expertise alongside a deep scientific and academic understanding of patients, disease mechanisms, and model systems. The intent is to translate cutting edge academic science into drug discovery, and to prosecute projects from target to lead status, and beyond. 

Housed within The Target Discovery Institute at the University of Oxford, the ODDI is uniting collaborative efforts for target identification with sophisticated target development capabilities. Led by the CSO, Dr John Davis, the ODDI focuses on novel targets in the dementia therapeutic area, bringing together researchers from Biology, Chemistry, Psychiatry, and Neuroscience. The institute is part of a newly formed, world-class, network of three drug discovery institutes, sponsored by Alzheimer’s Research UK. 

The Oxford Drug Discovery Institute is one of three Institutes within the Alzheimer’s Research UK Drug Discovery Alliance, working alongside Institutes at the University of Cambridge and University College London. The Alliance will accelerate the discovery of novel, effective therapeutics for Alzheimer’s disease and other neurodegenerative diseases.

Alzheimer’s Research UK unites more than 1000 dementia researchers from across the UK to support and streamline dementia research. The charity is dedicated to funding the best minds and forging the most effective partnerships to nurture discovery and ideas, as well as translating findings from this pioneering research into benefits for people with dementia. For more information, visit ARUK’s website.

News Feed

The Mighty Quiz for ARUK

The Mighty Quiz for ARUK

Posted 03/12/2018

This week saw the University of Oxford’s Old Road Campus play host to the Mighty Quiz and raffle, in support of Alzheimer’s Research UK. Quizzers from various groups and posts came together to battle it out for the title of Mightiest Quizzers, and to raise money for dementia research and awareness. Once teams had tackled the first task – choosing an award-winning name – they went head to head, answering general knowledge questions on a variety ...

The ARUK Oxford Drug Discovery institute hosts Lord O’Shaughnessy, Parliamentary Undersecretary of State for Health

External Link found on http://aruk-oddi.medsci.ox.ac.uk/latest-news

FORMA expands translational footprint in Neurodegeneration with ARUK Oxford Drug Discovery Institute

FORMA expands translational footprint in Neurodegeneration with ARUK Oxford Drug Discovery Institute

Posted 06/06/2018

FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases

Oxford, U.K. and Watertown, Massachusetts, USA – May 9th, 2018 – FORMA Therapeutics and the University of Oxford announced today they have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases..

All News